Application of silver nanoparticles in the treatment of central serous chorioretinopathy

被引:1
|
作者
Chen, Yao [1 ]
Su, Fanfan [1 ]
Su, Bo [2 ]
机构
[1] Yangtze Univ, Jingzhou Cent Hosp, Clin Med Coll 2, Dept Ophthalmol, Jingzhou 434020, Hubei, Peoples R China
[2] Yangtze Univ, Sch Med, Dept Pathol, Jingzhou 434023, Hubei, Peoples R China
关键词
Silver Nanoparticle; Central Serous Chorioretinopathy; Treatment; COMPOSITE FILM; DNA; NANOCLUSTERS; FLUORESCENCE;
D O I
10.1166/mex.2023.2353
中图分类号
TB3 [工程材料学];
学科分类号
0805 ; 080502 ;
摘要
The purpose of this study was to explore the therapeutic effect of silver nanoparticles in the treatment of central serous chorioretinopathy (CSC). After the establishment of CSC in New Zealand rabbits (n = 128), the animals were treated with iodized lecithin tablets by gavage (ILT only, n = 64) or ILT gavage followed by injection of silver nanoparticles into the vitreous cavity (SN, n = 64). The sum retinal layer thickness of SN group before gavage was lower than that of ILT group, and the total retinal thickness of SN group after gavage was also lower than that of ILT group. There were interaction effects between groups and time IP: 217 163 11 .10 On Tue 18 Apr 2023 14:08:13 (Fgroup effect = 42.570, Ftime effect = 19.250, Copyright: Finteraction American effect = 2.885,Scien allific <Publishers0.05).Electroretinograms showed lower peak latency in oscillatory potential (OP1, OP2, and OP3) in the SN group than in the ILT group before and after gavage (intergroup effect: F1 = 40.280, F2 = 52.760, F3 =133.700; time effect: F1 =10.330, F2 = 9.082, F3 = 93.760; interaction effects: F1 = 4.204, F2 = 3.059, F3 = 12.260; all P < 0.05). The b-wave amplitudes and total amplitudes were higher in the SN group than in the ILT group before and after gavage (intergroup effect: F1 = 10.540, F2 = 13.270; time effect: F1 = 25.910, F2 = 35.120; interaction effects: F1 = 2.817, F2 = 5.264; all P < 0.05). No significant differences in intraocular pressure were observed, and there were no interaction effects (Fintergroup effect = 0.046, Ftime effect = 0.001, Finteraction effect = 0.027, all P > 0.05). We conclude that silver nanoparticles provide a significant therapeutic effect on CSC in rabbits, ensuring the integrity of retinal morphology, structure, function, and limiting damage to visual function.
引用
收藏
页码:274 / 282
页数:9
相关论文
共 50 条
  • [31] Central Serous Chorioretinopathy
    Liegl, Raffael
    Ulbig, Michael W.
    OPHTHALMOLOGICA, 2014, 232 (02) : 65 - 76
  • [32] Central serous chorioretinopathy
    Pauleikhoff, Laurenz
    Agostini, Hansjurgen
    Lange, Clemens
    OPHTHALMOLOGE, 2021, 118 (09): : 967 - 980
  • [33] Differential diagnoses of central serous chorioretinopathy. Is that really a central serous chorioretinopathy?
    Lange, C.
    Aschauer, J.
    Hufnagel, H.
    Pauleikhoff, L.
    OPHTHALMOLOGIE, 2025, 122 (03): : 178 - 185
  • [34] CLINICAL APPLICATION OF MULTICOLOR IMAGING IN CENTRAL SEROUS CHORIORETINOPATHY
    He, Lu
    Chen, Changzheng
    Yi, Zuohuizi
    Wang, Xiaoling
    Liu, Juejun
    Zheng, Hongmei
    RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2020, 40 (04): : 743 - 749
  • [35] Diagnosis and Treatment of Central Serous Chorioretinopathy in Patients with Scleritis
    Tsai, Yu-Chien
    Chen, Yann-Guang
    Lee, Yueh-Chang
    Hwang, Yih-Shiou
    Hsieh, Yun-Hsiu
    MEDICINA-LITHUANIA, 2023, 59 (05):
  • [36] Treatment of central serous chorioretinopathy with mineralocorticoid receptor antagonists
    Cakir, B.
    Agostini, H.
    Lange, C.
    OPHTHALMOLOGE, 2019, 116 (02): : 189 - 200
  • [37] Ketoconazole in the treatment of central serous chorioretinopathy: a pilot study
    Golshahi, Azadeh
    Klingmueller, Dietrich
    Holz, Frank G.
    Eter, Nicole
    ACTA OPHTHALMOLOGICA, 2010, 88 (05) : 576 - 581
  • [38] Intravitreal bevacizumab for treatment of chronic central serous chorioretinopathy
    W-C Huang
    W-L Chen
    Y-Y Tsai
    C-C Chiang
    J-M Lin
    Eye, 2009, 23 : 488 - 489
  • [39] Photodynamic therapy in the treatment of chronic central serous chorioretinopathy
    Valmaggia, C
    Niederberger, H
    KLINISCHE MONATSBLATTER FUR AUGENHEILKUNDE, 2006, 223 (05) : 372 - 375
  • [40] Oral Mineralocorticoid Antagonists for the Treatment of Central Serous Chorioretinopathy
    Chin, Eric K.
    Almeida, David
    Russell, Stephen R.
    Folk, James C.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2014, 55 (13)